Positive data on new antidepressant from Lundbeck
Lundbeck have reported positive results from a phase III trial with a new antidepressant candidate from the Danish company.
by Kresten Morten Munksgaard
Lundbeck’s candidate drug, the antidepressant Brintellix, performs better than a possible rival drug, Valdoxan (agomelatin), in patients with major depression and inadequate response to SSRI or SNRI therapy, results from a recently concluded phase III trial with the two drugs indicate, according to a statement released on Monday.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
.jpg&w=384&q=75){kind=logo}
